Gensight Biologics SA Aktie
0,30 €
Deine Einschätzung
Gensight Biologics SA Aktie
Was spricht für und gegen Gensight Biologics SA in den nächsten Jahren?
Pro
Kontra
Rendite von Gensight Biologics SA im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | -3,50 % | -6,19 % | -14,77 % | -58,21 % | -31,60 % | -95,91 % | -78,48 % |
Celsion Corp. | 9,71 % | 13,57 % | -13,08 % | 0,00 % | 89,92 % | -92,23 % | -95,04 % |
India Globalization Capital | 11,30 % | 9,44 % | -4,83 % | 53,91 % | 50,38 % | -70,33 % | -70,00 % |
CEL-SCI Corp. | 2,50 % | -8,39 % | -6,60 % | -52,36 % | -59,38 % | -84,54 % | - |
Kommentare
News
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Appoints William Monteith to its Board of Directors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies